Lakefront Biotherapeutics NV
Business
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company focused on identifying, acquiring, and advancing clinical-stage programs in oncology and immunology & inflammation. The company's pipeline includes GLPG3667, a TYK2 inhibitor in Phase 2 for dermatomyositis and systemic lupus erythematosus, and cell therapy candidates being wound down. The company operates primarily through strategic business development, partnering with Gilead under a long-term collaboration agreement covering R&D and commercialization rights outside Europe.
Summary from 20-F filed 2026-03-26
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $320.88M |
| Total assets | $3.41B |
| Total liabilities | $170.65M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Lakefront Biotherapeutics NV's CIK number?
Lakefront Biotherapeutics NV's SEC CIK number is 0001421876 (1421876). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Lakefront Biotherapeutics NV's SEC filings?
All of Lakefront Biotherapeutics NV's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.